carnitine has been researched along with Hyperlipemia in 46 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To develop a therapeutic agent for obesity-related metabolic disorders, a mixture of dietary components was prepared, including grape extract, green tea extract and l-carnitine (RGTC), and its effects on obesity, hyperlipidemia and non-alcoholic fatty liver disease examined." | 7.77 | A combination of grape extract, green tea extract and L-carnitine improves high-fat diet-induced obesity, hyperlipidemia and non-alcoholic fatty liver disease in mice. ( Han, SB; Kang, JS; Kim, HM; Kim, N; Lee, CW; Lee, K; Lee, KH; Lee, WK; Ly, SY; Park, HK; Park, SK; Yoon, WK; Yun, J, 2011) |
| "Overweight patients with hyperlipidemia (serum triglyceride ≥ 1." | 6.80 | Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial. ( Du, S; Jiang, S; Li, Y; Na, L; Niu, Y; Sun, C; Zhang, Q; Zhang, W, 2015) |
| "This study was designed to investigate the effect of hypercholesterolemia on the reproductive performance of premature male rats and to evaluate the influence of L-Carnitine (CAR) in maintaining their fertility." | 5.51 | L-Carnitine effect on induced hyperlipidemia on premature rats: fertility profile. ( Al-Delemi, DHJ; Al-Nailey, KGC; Alebady, AS; Karam, KM, 2022) |
| " Serum markers of endothelial dysfunction and inflammation were unchanged, but short-chain acylcarnitine concentrations were significantly decreased." | 3.79 | Daily non-soy legume consumption reverses vascular impairment due to peripheral artery disease. ( Baldwin, A; Blewett, H; Guzman, RP; O, K; Taylor, CG; Weighell, W; Wright, B; Zahradka, P, 2013) |
| "To develop a therapeutic agent for obesity-related metabolic disorders, a mixture of dietary components was prepared, including grape extract, green tea extract and l-carnitine (RGTC), and its effects on obesity, hyperlipidemia and non-alcoholic fatty liver disease examined." | 3.77 | A combination of grape extract, green tea extract and L-carnitine improves high-fat diet-induced obesity, hyperlipidemia and non-alcoholic fatty liver disease in mice. ( Han, SB; Kang, JS; Kim, HM; Kim, N; Lee, CW; Lee, K; Lee, KH; Lee, WK; Ly, SY; Park, HK; Park, SK; Yoon, WK; Yun, J, 2011) |
| "Hyperlipidemia is a key risk factor for cardiovascular disease, and it is associated with lipid metabolic disorders and gut microbiota dysbiosis." | 3.30 | Probio-X Relieves Symptoms of Hyperlipidemia by Regulating Patients' Gut Microbiome, Blood Lipid Metabolism, and Lifestyle Habits. ( A, L; Guo, R; Han, H; Li, Y; Ma, C; Shang, D; Sun, Z; Wang, H; Yang, C; Yang, F; Zhang, H; Zhang, L; Zhang, Y; Zhao, F, 2023) |
| "Overweight patients with hyperlipidemia (serum triglyceride ≥ 1." | 2.80 | Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial. ( Du, S; Jiang, S; Li, Y; Na, L; Niu, Y; Sun, C; Zhang, Q; Zhang, W, 2015) |
| "Hyperlipidemia and obesity are associated with metabolic syndrome and increased risk in developing diabetes and cardiovascular disease." | 2.76 | A combination of (ω-3) polyunsaturated fatty acids, polyphenols and L-carnitine reduces the plasma lipid levels and increases the expression of genes involved in fatty acid oxidation in human peripheral blood mononuclear cells and HepG2 cells. ( Anderwald, C; Anzur, C; Brachinger, M; Eller-Berndl, D; Fischer, A; Krepp, R; Laschan, C; Lechner, S; Lienbacher, G; Lohninger, A; Mascher, D; Radler, U; Schoerg, G; Stangl, H; Zeller, E, 2011) |
| "L-carnitine was randomly administered to 81 patients at an oral dose of g 4/die for 12 months, in addition to the pharmacological treatment generally used." | 2.67 | Controlled study on L-carnitine therapeutic efficacy in post-infarction. ( Bigalli, A; Boem, A; Davini, P; Lamanna, F, 1992) |
| "Carnitine is a selective carrier of free fatty acids from the cytoplasm to the mitochondria." | 2.65 | L-carnitine in haemodialysed patients. Changes in lipid pattern. ( Caruso, U; Casciani, CU; Corsi, M; Cravotto, E; D'Iddio, S; Grilli, M; Pola, P; Savi, L, 1982) |
| "Hyperlipidemia is a risk factor for initiation and progression of diabetic nephropathy but the metabolic pathways altered in the diabetic kidney in a context of hyperlipidemia remain incompletely described." | 1.46 | Increased urine acylcarnitines in diabetic ApoE-/- mice: Hydroxytetradecadienoylcarnitine (C14:2-OH) reflects diabetic nephropathy in a context of hyperlipidemia. ( Bascands, JL; Denis, C; Gillet, M; Klavins, K; Klein, J; Koal, T; Marsal, D; Mirzoyan, K; Saulnier-Blache, JS; Schanstra, JP, 2017) |
| "Refeeding syndrome has been observed in patients receiving nutrition after a prolonged period of malnourishment and is characterized by multiple metabolic derangements." | 1.38 | Fatty emaciation: a case report of suspected fat overload syndrome in oral refeeding. ( Macher, AD; Maviglia, SM; Palazuelos, D, 2012) |
| "Severe hyperlipidemia was reversed by changing the carnitine deficient diet (Ensureliquid) to a carnitine-containing diet." | 1.32 | A case of severe hyperlipidemia caused by long-term tube feedings. ( Hsieh, ST; Ishikawa, Y; Kim, JI; Miki, T; Tanaka, S; Taniguchi, T; Yasumoto, T; Yokoyama, M, 2003) |
| "Iron deficiency anemia and hyperlipidemia are common public health problems in Turkey." | 1.31 | Serum free carnitine and total triglycerid levels in children with iron deficiency anemia. ( Cetinkaya, O; Hizel, S; Sekreter, E; Tanzer, F, 2001) |
| "L-carnitine treatment had no effect on the FCRs of VLDL-TG and VLDL-apoB or on the transport of VLDL-apoB." | 1.29 | Effect of L-carnitine treatment on very low density lipoprotein kinetics in the hyperlipidemic rabbit. ( Bhuiyan, AK; Foster, D; James, L; Seccombe, D, 1995) |
| " At the end of the experimental protocol, L-carnitine dosage was increased to 60 mg/kg iv (at the end of each dialysis) in four patients of the group of nonresponders and prolonged for 60 days." | 1.27 | Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: decisive role of low levels of high-density lipoprotein-cholesterol. ( Corsi, M; Giorcelli, G; Siliprandi, N; Vacha, GM, 1983) |
| "Carnitine pretreatment stimulated ketogenesis." | 1.27 | L-carnitine effect on plasma lipoproteins of hyperlipidemic fat-loaded rats. ( Angelucci, L; Arseni, A; Chiodi, P; Hulsmann, WC; Maccari, F; Ramacci, MT, 1987) |
| "3." | 1.27 | The influence of diet and carnitine supplementation on plasma carnitine, cholesterol and triglyceride in WHHL (Watanabe-heritable hyperlipidemic), Netherland dwarf and New Zealand rabbits (Oryctolagus cuniculus). ( Bell, FP; Patnode, CL; Raymond, TL, 1987) |
| "L-carnitine was found to reduce the level of myocardial long-chain acylcarnitine which was increased by the olive oil treatment." | 1.27 | The effect of exogenous L-carnitine on biochemical parameters in serum and in heart of the hyperlipidaemic rat. ( Angelucci, L; Arseni, A; Chiodi, P; Maccari, F; Ramacci, MT, 1987) |
| "L-Carnitine treatment blunted the magnitude of the diet induced increase in 7 alpha-hydroxylase activity, yet overall the activity still remained elevated relative to controls." | 1.27 | L-carnitine treatment in the hyperlipidemic rabbit. ( Hahn, P; James, L; Jones, E; Seccombe, DW, 1987) |
| "Oral carnitine has been reported to have a lipid-lowering effect with concomitant elevation of high density lipoprotein cholesterol (HDL-C) levels in normo- and hyperlipidemic individuals." | 1.27 | Plasma carnitine and lipid-lowering drugs. ( Davignon, J; Nestruck, AC; Pande, SV, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (50.00) | 18.7374 |
| 1990's | 6 (13.04) | 18.2507 |
| 2000's | 5 (10.87) | 29.6817 |
| 2010's | 10 (21.74) | 24.3611 |
| 2020's | 2 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Karam, KM | 1 |
| Alebady, AS | 1 |
| Al-Nailey, KGC | 1 |
| Al-Delemi, DHJ | 1 |
| Wang, H | 1 |
| Ma, C | 1 |
| Li, Y | 2 |
| Zhang, L | 1 |
| A, L | 1 |
| Yang, C | 1 |
| Zhao, F | 1 |
| Han, H | 1 |
| Shang, D | 1 |
| Yang, F | 1 |
| Zhang, Y | 1 |
| Zhang, H | 1 |
| Sun, Z | 1 |
| Guo, R | 1 |
| Nie, Q | 1 |
| Xing, M | 1 |
| Chen, H | 1 |
| Hu, J | 1 |
| Nie, S | 1 |
| Mirzoyan, K | 1 |
| Klavins, K | 1 |
| Koal, T | 1 |
| Gillet, M | 1 |
| Marsal, D | 1 |
| Denis, C | 1 |
| Klein, J | 1 |
| Bascands, JL | 1 |
| Schanstra, JP | 1 |
| Saulnier-Blache, JS | 1 |
| Zahradka, P | 1 |
| Wright, B | 1 |
| Weighell, W | 1 |
| Blewett, H | 1 |
| Baldwin, A | 1 |
| O, K | 1 |
| Guzman, RP | 1 |
| Taylor, CG | 1 |
| Fiamoncini, J | 1 |
| Lima, TM | 1 |
| Hirabara, SM | 1 |
| Ecker, J | 1 |
| Gorjão, R | 1 |
| Romanatto, T | 1 |
| ELolimy, A | 1 |
| Worsch, S | 1 |
| Laumen, H | 1 |
| Bader, B | 1 |
| Daniel, H | 1 |
| Curi, R | 1 |
| Na, L | 1 |
| Zhang, Q | 1 |
| Jiang, S | 1 |
| Du, S | 1 |
| Zhang, W | 1 |
| Sun, C | 1 |
| Niu, Y | 1 |
| Allam-Ndoul, B | 1 |
| Guénard, F | 1 |
| Garneau, V | 1 |
| Cormier, H | 1 |
| Barbier, O | 1 |
| Pérusse, L | 1 |
| Vohl, MC | 1 |
| Kang, JS | 1 |
| Lee, WK | 1 |
| Yoon, WK | 1 |
| Kim, N | 1 |
| Park, SK | 2 |
| Park, HK | 1 |
| Ly, SY | 1 |
| Han, SB | 1 |
| Yun, J | 1 |
| Lee, CW | 1 |
| Lee, K | 1 |
| Lee, KH | 1 |
| Kim, HM | 1 |
| Radler, U | 1 |
| Stangl, H | 1 |
| Lechner, S | 1 |
| Lienbacher, G | 1 |
| Krepp, R | 1 |
| Zeller, E | 1 |
| Brachinger, M | 1 |
| Eller-Berndl, D | 1 |
| Fischer, A | 1 |
| Anzur, C | 1 |
| Schoerg, G | 1 |
| Mascher, D | 1 |
| Laschan, C | 1 |
| Anderwald, C | 1 |
| Lohninger, A | 1 |
| Macher, AD | 1 |
| Palazuelos, D | 1 |
| Maviglia, SM | 1 |
| Wanner, C | 2 |
| Wieland, H | 1 |
| Nauck, M | 1 |
| Schaeffer, G | 1 |
| Schollmeyer, P | 1 |
| Hörl, WH | 2 |
| Reimann, M | 1 |
| Peitzsch, M | 1 |
| Ziemssen, T | 1 |
| Julius, U | 1 |
| Eisenhofer, G | 1 |
| Merkel, M | 1 |
| Greten, H | 1 |
| BEKAERT, J | 1 |
| DELTOUR, G | 1 |
| Tanaka, S | 1 |
| Miki, T | 1 |
| Hsieh, ST | 1 |
| Kim, JI | 1 |
| Yasumoto, T | 1 |
| Taniguchi, T | 1 |
| Ishikawa, Y | 1 |
| Yokoyama, M | 1 |
| Güneş, B | 1 |
| Yalçin, SS | 1 |
| Kalkanoğlu, HS | 1 |
| Onol, S | 1 |
| Dursun, A | 1 |
| Coşkun, T | 1 |
| Vacha, GM | 1 |
| Giorcelli, G | 1 |
| Siliprandi, N | 1 |
| Corsi, M | 2 |
| Maebashi, M | 2 |
| Imamura, A | 2 |
| Yoshinaga, K | 2 |
| Sato, T | 1 |
| Funyu, T | 1 |
| Ishidoya, Y | 1 |
| Hirayama, N | 1 |
| Albertazzi, A | 1 |
| Capelli, P | 1 |
| Di Paolo, B | 1 |
| Pola, P | 2 |
| Tondi, P | 1 |
| Vaccario, O | 1 |
| Casciani, CU | 1 |
| Caruso, U | 1 |
| Cravotto, E | 1 |
| D'Iddio, S | 1 |
| Savi, L | 1 |
| Grilli, M | 1 |
| Bertoli, M | 1 |
| Battistella, PA | 1 |
| Vergani, L | 1 |
| Naso, A | 1 |
| Gasparotto, ML | 1 |
| Romagnoli, GF | 1 |
| Angelini, C | 1 |
| Spagnoli, LG | 1 |
| Orlandi, A | 1 |
| Marino, B | 1 |
| Mauriello, A | 1 |
| De Angelis, C | 1 |
| Ramacci, MT | 5 |
| James, L | 2 |
| Bhuiyan, AK | 1 |
| Foster, D | 1 |
| Seccombe, D | 1 |
| Sirtori, CR | 1 |
| Calabresi, L | 1 |
| Ferrara, S | 1 |
| Pazzucconi, F | 1 |
| Bondioli, A | 1 |
| Baldassarre, D | 1 |
| Birreci, A | 1 |
| Koverech, A | 1 |
| Tanzer, F | 1 |
| Hizel, S | 1 |
| Cetinkaya, O | 1 |
| Sekreter, E | 1 |
| Kawamura, N | 1 |
| Sato, M | 1 |
| Bougneres, PF | 1 |
| Lacour, B | 1 |
| di Giulio, S | 1 |
| Assan, R | 1 |
| Davini, P | 1 |
| Bigalli, A | 1 |
| Lamanna, F | 1 |
| Boem, A | 1 |
| Dhalla, NS | 1 |
| Elimban, V | 1 |
| Rupp, H | 1 |
| Mimura, K | 1 |
| Yukawa, S | 1 |
| Raymond, TL | 2 |
| Reynolds, SA | 1 |
| Swanson, JA | 1 |
| Patnode, CA | 1 |
| Bell, FP | 2 |
| Maccari, F | 4 |
| Arseni, A | 3 |
| Chiodi, P | 3 |
| Angelucci, L | 4 |
| Hulsmann, WC | 1 |
| Rebouche, CJ | 1 |
| Paulson, DJ | 1 |
| Kendler, BS | 1 |
| Patnode, CL | 1 |
| Wakabayashi, Y | 1 |
| Okubo, M | 1 |
| Shimada, H | 1 |
| Sato, N | 1 |
| Koide, A | 1 |
| Marumo, F | 1 |
| Nakamura, H | 1 |
| Seccombe, DW | 1 |
| Hahn, P | 1 |
| Jones, E | 1 |
| Novoa, D | 1 |
| Rodriguez-Segade, S | 1 |
| Romero, R | 1 |
| Arcocha, V | 1 |
| Alonso de la Peña, C | 1 |
| Paz, M | 1 |
| del Río, A | 1 |
| del Río, R | 1 |
| Borum, PR | 1 |
| Taggart, EM | 1 |
| Pessotto, P | 1 |
| Nestruck, AC | 1 |
| Pande, SV | 1 |
| Davignon, J | 1 |
| Szamosi, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Blinded, Randomized, Controlled Study to Examine the Bioavailability of Compounds From Different Bean Varieties in Healthy Individuals.[NCT02342340] | 8 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| Correlation Between Carnitine Deficiency and Hypoglycemic Events in Type I Diabetes; Effects of Carnitine Supplementation on Hypoglycemic Events in Type I Diabetes[NCT00351234] | 200 participants (Actual) | Observational | 2004-10-31 | Completed | |||
| In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075] | Phase 1 | 42 participants | Interventional | 2003-09-30 | Completed | ||
| Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266] | Phase 2 | 94 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months
| Intervention | g (Mean) | |||||
|---|---|---|---|---|---|---|
| Lean Mass Baseline | Lean Mass 3 months | Lean Mass 6 months | Fat Mass Baseline | Fat Mass 3 months | Fat Mass 6 months | |
| SMA Type 1 | 4317.15 | 4993.92 | 5133.83 | 3011.37 | 3618.25 | 4316.08 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 2.28 | 2.32 |
| Cohort 1b Sitters Treatment | 2.93 | 2.37 |
| Cohort 2 Standers and Walkers - Treatment | 5.52 | 6.56 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 1.91 | 1.44 |
| Cohort 1b Sitters Treatment | 2.2 | 1.8 |
| Cohort 2 Standers and Walkers - Treatment | 5.3 | 5.85 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 5.46 | 5.28 |
| Cohort 1b Sitters Treatment | 5.45 | 5.26 |
| Cohort 2 Standers and Walkers - Treatment | 14.85 | 16.26 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 3.6 | 3.74 |
| Cohort 1b Sitters Treatment | 4.6 | 3.4 |
| Cohort 2 Standers and Walkers - Treatment | 13.65 | 16.85 |
Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Baseline visit (0 weeks) | 6 Month visit (V2) | Change from Baseline | |
| Cohort 1a Sitters Placebo Then Treatment | 20.0 | 20.6 | 0.6 |
| Cohort 1b Sitters Treatment | 16.6 | 16.8 | 0.2 |
"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)
| Intervention | Score (Mean) | |
|---|---|---|
| Modified Hammersmith Extend at S1 (-4 weeks) | Modified Hammersmith Extend at S2 (0 weeks) | |
| Cohort 2 Experimental | 47.0 | 48.3 |
3 reviews available for carnitine and Hyperlipemia
| Article | Year |
|---|---|
Paradoxical role of lipid metabolism in heart function and dysfunction.
Topics: Adenosine Triphosphatases; Animals; Carnitine; Diabetes Complications; Diabetes Mellitus; Diabetes M | 1992 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine metabolism and function in humans.
Topics: Absorption; Acidosis; Adolescent; Adult; Aged; Animals; Biological Transport; Cardiomyopathies; Carn | 1986 |
Carnitine: an overview of its role in preventive medicine.
Topics: Animals; Cardiovascular Diseases; Carnitine; Humans; Hyperlipidemias; Infant, Newborn | 1986 |
9 trials available for carnitine and Hyperlipemia
| Article | Year |
|---|---|
L-Carnitine effect on induced hyperlipidemia on premature rats: fertility profile.
Topics: Animals; Carnitine; Fertility; Follicle Stimulating Hormone; Hypercholesterolemia; Hyperlipidemias; | 2022 |
Probio-X Relieves Symptoms of Hyperlipidemia by Regulating Patients' Gut Microbiome, Blood Lipid Metabolism, and Lifestyle Habits.
Topics: Bifidobacterium animalis; Carnitine; Cholesterol; Gastrointestinal Microbiome; Humans; Hyperlipidemi | 2023 |
Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Blood Glucose; Carnitine; Cholesterol, HDL; Dietary Supplement | 2015 |
A combination of (ω-3) polyunsaturated fatty acids, polyphenols and L-carnitine reduces the plasma lipid levels and increases the expression of genes involved in fatty acid oxidation in human peripheral blood mononuclear cells and HepG2 cells.
Topics: Adult; Carnitine; Double-Blind Method; Fatty Acids; Fatty Acids, Omega-3; Female; Flavonoids; Functi | 2011 |
Effective hypolipidaemic therapy with beclobrate in haemodialysis patients: interference with L-carnitine.
Topics: Benzhydryl Compounds; Carnitine; Cholesterol; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; | 1990 |
L-carnitine in haemodialysed patients. Changes in lipid pattern.
Topics: Adult; Carnitine; Female; Humans; Hyperlipidemias; Lipids; Male; Renal Dialysis | 1982 |
L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a).
Topics: Aged; Cardiovascular Diseases; Carnitine; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypo | 2000 |
Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinaemia.
Topics: Administration, Oral; Adult; Blood Glucose; Carnitine; Cholesterol; Fatty Acids, Nonesterified; Huma | 1978 |
Controlled study on L-carnitine therapeutic efficacy in post-infarction.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Carnitine; Fe | 1992 |
34 other studies available for carnitine and Hyperlipemia
| Article | Year |
|---|---|
Metabolomics and Lipidomics Profiling Reveals Hypocholesterolemic and Hypolipidemic Effects of Arabinoxylan on Type 2 Diabetic Rats.
Topics: Amino Acids, Branched-Chain; Animals; Anticholesteremic Agents; Bile Acids and Salts; Carnitine; Dia | 2019 |
Increased urine acylcarnitines in diabetic ApoE-/- mice: Hydroxytetradecadienoylcarnitine (C14:2-OH) reflects diabetic nephropathy in a context of hyperlipidemia.
Topics: Animals; Apolipoproteins E; Biomarkers; Carnitine; Diabetic Nephropathies; Hyperlipidemias; Male; Mi | 2017 |
Daily non-soy legume consumption reverses vascular impairment due to peripheral artery disease.
Topics: Aged; Aged, 80 and over; Ankle Brachial Index; Atherosclerosis; Biomarkers; Carnitine; Carotid Steno | 2013 |
Medium-chain dicarboxylic acylcarnitines as markers of n-3 PUFA-induced peroxisomal oxidation of fatty acids.
Topics: Animals; Biomarkers; Carnitine; Diet, High-Fat; Dietary Fats; Dietary Fats, Unsaturated; Fatty Acids | 2015 |
Association between Metabolite Profiles, Metabolic Syndrome and Obesity Status.
Topics: Adult; Amino Acids; Body Mass Index; Cardiovascular Diseases; Carnitine; Cholesterol; Cholesterol, H | 2016 |
A combination of grape extract, green tea extract and L-carnitine improves high-fat diet-induced obesity, hyperlipidemia and non-alcoholic fatty liver disease in mice.
Topics: Adipose Tissue; Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Carnitine; | 2011 |
Fatty emaciation: a case report of suspected fat overload syndrome in oral refeeding.
Topics: Administration, Oral; Anorexia Nervosa; Carnitine; Dietary Fats; Female; Humans; Hyperlipidemias; Ma | 2012 |
Metabolomic distinction of microvascular effects of lipoprotein apheresis--a pilot study.
Topics: Adult; Aged; Biomarkers; Blood Component Removal; Carnitine; Chi-Square Distribution; Decision Trees | 2013 |
[L-carnitine and lipid lowering].
Topics: Adipose Tissue; Carnitine; Energy Metabolism; Humans; Hyperlipidemias; Lipid Metabolism; Lipids; Mus | 2003 |
[Effect of carnitine on diabetic hyperlipemia].
Topics: Carnitine; Diabetes Complications; Diabetes Mellitus; Folic Acid; Humans; Hyperlipidemias; Lipids; V | 1960 |
A case of severe hyperlipidemia caused by long-term tube feedings.
Topics: Aged; Carnitine; Dietary Sucrose; Enteral Nutrition; Female; Food, Formulated; Humans; Hyperlipidemi | 2003 |
The effect of oral L-carnitine supplementation on the lipid profiles of hyperlipidaemic children.
Topics: Administration, Oral; Carnitine; Child; Cholesterol; Dietary Supplements; Female; Humans; Hyperlipid | 2005 |
Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: decisive role of low levels of high-density lipoprotein-cholesterol.
Topics: Adult; Apolipoproteins; Apolipoproteins A; Carnitine; Cholesterol; Cholesterol, HDL; Female; Humans; | 1983 |
Carnitine depletion as a probable cause of hyperlipidemia in uremic patients on maintenance hemodialysis.
Topics: Adult; Amino Acids; Carnitine; Humans; Hyperlipidemias; Kinetics; Middle Aged; Renal Dialysis; Trigl | 1983 |
Endocrine-metabolic effects of l-carnitine in patients on regular dialysis treatment.
Topics: Acetylcarnitine; Adolescent; Adult; Aged; Carnitine; Cholesterol; Cholesterol, HDL; Female; Hormones | 1983 |
Carnitine deficiency induced during hemodialysis and hyperlipidemia: effect of replacement therapy.
Topics: Adult; Carnitine; Female; Humans; Hyperlipidemias; Lipid Metabolism; Male; Middle Aged; Muscles; Ren | 1981 |
Propionyl-L-carnitine prevents the progression of atherosclerotic lesions in aged hyperlipemic rabbits.
Topics: Aging; Animals; Arteriosclerosis; Carnitine; Cell Division; Diet; Disease Models, Animal; Female; Fo | 1995 |
Effect of L-carnitine treatment on very low density lipoprotein kinetics in the hyperlipidemic rabbit.
Topics: Animals; Apolipoproteins B; Carnitine; Dietary Fats; Glycerol; Hyperlipidemias; Lipoproteins, VLDL; | 1995 |
Serum free carnitine and total triglycerid levels in children with iron deficiency anemia.
Topics: Anemia, Iron-Deficiency; Cardiovascular Diseases; Carnitine; Case-Control Studies; Cholesterol; Fema | 2001 |
Hypolipaemic effect of carnitine in uraemic patients.
Topics: Carnitine; Humans; Hyperlipidemias; Triglycerides; Uremia | 1979 |
[Hyperlipidemia and drug treatment].
Topics: Arteriosclerosis; Carnitine; Cholestyramine Resin; Glomerulonephritis; Humans; Hyperlipidemias; Kidn | 1991 |
The effect of oral l-carnitine on lipoprotein composition in the Watanabe Heritable Hyperlipidemic Rabbit (Oryctolagus cuniculus).
Topics: Animals; Carnitine; Cholesterol; Hyperlipidemias; Lipoproteins; Rabbits; Triglycerides | 1987 |
Potential role of carnitine in patients with renal insufficiency.
Topics: Acetylcarnitine; Carnitine; Carnitine O-Palmitoyltransferase; Creatinine; Humans; Hyperlipidemias; K | 1986 |
L-carnitine effect on plasma lipoproteins of hyperlipidemic fat-loaded rats.
Topics: Animals; Carnitine; Chylomicrons; Dietary Fats, Unsaturated; Fatty Acids, Nonesterified; Female; Hyp | 1987 |
[Effect of L-carnitine on various biochemical parameters of the heart, liver and serum of the hyperlipemic rat].
Topics: Animals; Carnitine; Hyperlipidemias; Lipid Metabolism; Liver; Male; Myocardium; Random Allocation; R | 1986 |
The influence of diet and carnitine supplementation on plasma carnitine, cholesterol and triglyceride in WHHL (Watanabe-heritable hyperlipidemic), Netherland dwarf and New Zealand rabbits (Oryctolagus cuniculus).
Topics: Animals; Carnitine; Cholesterol; Diet; Female; Hyperlipidemias; Male; Rabbits; Triglycerides | 1987 |
Decreased VLDL apoprotein CII/apoprotein CIII ratio may be seen in both normotriglyceridemic and hypertriglyceridemic patients on chronic hemodialysis treatment.
Topics: Adult; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Carnitine; Fem | 1987 |
The effect of exogenous L-carnitine on biochemical parameters in serum and in heart of the hyperlipidaemic rat.
Topics: Animals; Carnitine; Dietary Fats, Unsaturated; Hyperlipidemias; Male; Myocardium; Olive Oil; Plant O | 1987 |
L-carnitine treatment in the hyperlipidemic rabbit.
Topics: Animals; Body Weight; Carnitine; Dietary Fats; Fatty Liver; Hyperlipidemias; Hypolipidemic Agents; L | 1987 |
Carnitine levels and hypertriglyceridemia in undialyzed patients.
Topics: Carnitine; Female; Humans; Hyperlipidemias; Kidney Failure, Chronic; Male; Renal Dialysis; Triglycer | 1987 |
Carnitine nutriture of dialysis patients.
Topics: Arrhythmias, Cardiac; Carnitine; Humans; Hyperlipidemias; Muscular Diseases; Nutritional Requirement | 1986 |
The effect of exogenous L-carnitine on fat diet-induced hyperlipidemia in the rat.
Topics: Acetylcarnitine; Acylation; Animals; Carnitine; Dietary Fats; Fatty Acids, Nonesterified; Feces; Hyp | 1985 |
Plasma carnitine and lipid-lowering drugs.
Topics: Carnitine; Cholesterol, HDL; Clofibrate; Female; Humans; Hyperlipidemia, Familial Combined; Hyperlip | 1985 |
Alterations of fatty acid metabolism in liver cells of hyperlipaemic old rats.
Topics: Acetates; Aging; Animals; Carbon Isotopes; Carnitine; Coenzyme A; Cytoplasm; Fatty Acids; Fatty Acid | 1972 |